Berbis Julie, Michel Gérard, Baruchel André, Bertrand Yves, Chastagner Pascal, Demeocq François, Kanold Justyna, Leverger Guy, Plantaz Dominique, Poirée Marilyne, Stephan Jean-Louis, Auquier Pascal, Contet Audrey, Dalle Jean-Hugues, Ducassou Stéphane, Gandemer Virginie, Lutz Patrick, Sirvent Nicolas, Tabone Marie-Dominique, Thouvenin-Doulet Sandrine
EA3279, Self-perceived Health Assessment Research Unit, School of Medicine, Aix-Marseilles University, Marseilles 13385, France, Department of Paediatric Onco-haematology, APHM, La Timone Hospital, Marseilles, France, Department of Paediatric Onco-haematology, APHP, Saint Louis Hospital, Paris, France, Department of Paediatric Onco-haematology, APHP, Robert Debré Hospital, Paris, France, Department of Paediatric Onco-haematology, HCL, Lyon, France, Department of Paediatric Onco-haematology, University Hospital of Nancy, Nancy, France, CHU Clermont-Ferrand, Department of Paediatric Onco-haematology, CIC Inserm 501, Clermont-Ferrand, France, Department of Paediatric Onco-haematology, APHP, GHUEP, Armand Trousseau Hospital, Paris 75012, France, Department of Paediatric Onco-haematology, University Hospital of Grenoble, Grenoble, France, Department of Paediatric Onco-haematology, University Hospital of Nice, Nice, France and Department of Paediatric Onco-haematology, University Hospital of Saint-Etienne, Saint-Etienne, France
EA3279, Self-perceived Health Assessment Research Unit, School of Medicine, Aix-Marseilles University, Marseilles 13385, France, Department of Paediatric Onco-haematology, APHM, La Timone Hospital, Marseilles, France, Department of Paediatric Onco-haematology, APHP, Saint Louis Hospital, Paris, France, Department of Paediatric Onco-haematology, APHP, Robert Debré Hospital, Paris, France, Department of Paediatric Onco-haematology, HCL, Lyon, France, Department of Paediatric Onco-haematology, University Hospital of Nancy, Nancy, France, CHU Clermont-Ferrand, Department of Paediatric Onco-haematology, CIC Inserm 501, Clermont-Ferrand, France, Department of Paediatric Onco-haematology, APHP, GHUEP, Armand Trousseau Hospital, Paris 75012, France, Department of Paediatric Onco-haematology, University Hospital of Grenoble, Grenoble, France, Department of Paediatric Onco-haematology, University Hospital of Nice, Nice, France and Department of Paediatric Onco-haematology, University Hospital of Saint-Etienne, Saint-Etienne, France.
Int J Epidemiol. 2015 Feb;44(1):49-57. doi: 10.1093/ije/dyu031. Epub 2014 Mar 17.
The main aim of the Leucémies de l'Enfant et l'Adolescent (LEA) project (Childhood and Adolescent Leukaemia) is to study the determinants (medical, socioeconomic, behavioural and environmental) of medium- and long-term outcomes of patients treated for childhood acute leukaemia (AL). The LEA study began in 2004 and is based on a French multicentric prospective cohort. Included are children treated for AL since January 1980 (incident and prevalent cases), surviving at month 24 for myeloblastic AL and lymphoblastic AL grafted in first complete remission or at month 48 for lymphoblastic AL not grafted in first complete remission. Information is collected during specific medical visits and notably includes the following data: socioeconomic data, AL history, physical late effects (such as fertility, cardiac function and metabolic syndrome) and quality of life. Data are collected every 2 years until the patient is 20 years old and has had a 10-year follow-up duration from diagnosis or last relapse. Thereafter, assessments are planned every 4 years. In active centres in 2013, eligible patients number more than 3000. The cohort has already included 2385 survivors, with rate of exhaustiveness of almost 80%. Data access can be requested from principal coordinators and must be approved by the steering committee.
儿童与青少年白血病(LEA)项目(儿童及青少年白血病)的主要目标是研究接受儿童急性白血病(AL)治疗患者中长期预后的决定因素(医学、社会经济、行为和环境方面)。LEA研究始于2004年,基于一个法国多中心前瞻性队列。纳入的是自1980年1月起接受AL治疗的儿童(新发病例和现患病例),对于在首次完全缓解期进行移植的髓细胞性AL和淋巴细胞性AL,在第24个月存活;对于未在首次完全缓解期进行移植的淋巴细胞性AL,在第48个月存活。在特定的医疗就诊期间收集信息,特别包括以下数据:社会经济数据、AL病史、身体远期影响(如生育能力、心功能和代谢综合征)以及生活质量。每2年收集一次数据,直至患者年满20岁且自诊断或最后一次复发后有10年的随访期。此后,计划每4年进行一次评估。在2013年的活跃中心,符合条件的患者超过3000人。该队列已纳入2385名幸存者,完整性率近80%。可向主要协调员申请数据访问,且必须经指导委员会批准。